.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

REQUIP Drug Profile

« Back to Dashboard
Requip is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. It is available from three suppliers. There are two patents protecting this drug and nine Paragraph IV challenges.

The generic ingredient in REQUIP is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

Summary for Tradename: REQUIP

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Drug Prices: :see details

Pharmacology for Tradename: REQUIP

Drug ClassNonergot Dopamine Agonist
Mechanism of ActionDopamine Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-001Sep 19, 1997RXYes► subscribe► subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-005Oct 31, 2008RXNo7,927,624► subscribeY ► subscribe
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-005Sep 19, 1997RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: REQUIP

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-005Sep 19, 19974,824,860► subscribe
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-004Sep 19, 19974,452,808► subscribe
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-004Sep 19, 19974,824,860► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: REQUIP

Drugname Dosage Strength RLD Submissiondate
ropinirole hydrochloride*Extended-release Tablets3 mgRequip XL1/8/2009
ropinirole hydrochlorideExtended-release Tablets6 mgRequip XL7/22/2009
ropinirole hydrochlorideExtended-release Tablets12 mgRequip XL2/5/2009
ropinirole hydrochlorideExtended-release Tablets3 mgRequip XL1/8/2009
ropinirole hydrochlorideExtended-release Tablets8 mgRequip XL11/3/2008
ropinirole hydrochlorideExtended-release Tablets4 mgRequip XL10/31/2008
ropinirole hydrochloride Extended-release Tablets2 mgRequip XL10/14/2008
ropinirole hydrochlorideTablets3 mg, 4 mg and 5 mgRequip2/4/2005
ropinirole hydrochlorideTablets0.25 mg, 0.5 mg, 1 mg and 2 mgRequip12/22/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc